{"id":5,"date":"2023-05-22T11:33:29","date_gmt":"2023-05-22T11:33:29","guid":{"rendered":"https:\/\/roctavianhcp-dev-001.azurewebsites.net\/en-us-new\/roctavian\/?page_id=5"},"modified":"2023-12-21T09:51:54","modified_gmt":"2023-12-21T09:51:54","slug":"home","status":"publish","type":"page","link":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/","title":{"rendered":"Home"},"content":{"rendered":"
\n\t
<\/div>\n\t
<\/div>\n\t
<\/div>\n\n\t
\n\t\t
\n\t\t\t\t\t\t \"\" \t\t<\/div>\n\t\t
\n
\n
\n

The only one-time gene therapy indicated for the treatment of severe hemophilia A in eligible adults1<\/sup><\/p>\n <\/div>\n

\n

Why roctavian?<\/a><\/p>\n <\/div>\n <\/div>\n <\/div>\n

\n

At Year 3, within the rollover population from the Phase 3 study, participants (n=97) had a mean (SD) Factor VIII activity level of 33.8 (47.6)\u00a0IU\/dL (via one-stage assay).1<\/sup><\/small><\/p>\n <\/div>\n\t\t \t\t\t<\/div>\n<\/div>\n\n\n

\n\t
\n\t\t
\n\t\t\t
\n\t\t\t \t\t\t\t\t\t\t<\/div>\n\t\t\t
\n\t\t\t \n
\n \t \"An\t
\n

A one-time gene therapy designed for Factor VIII production1<\/sup>\n<\/h4>\n \n \n <\/div>\n
\n \n

Explore how<\/a><\/p>\n <\/div>\n<\/div>\n\n

\n \t \"A\t
\n

Learn more about the efficacy of ROCTAVIAN\n<\/h4>\n \n \n <\/div>\n
\n \n

See efficacy data<\/a><\/p>\n <\/div>\n<\/div>\n\n

\n \t \"A\t
\n

Whether administering or referring patients, the first step is eligibility testing\n<\/h4>\n \n \n <\/div>\n
\n \n

Review Criteria<\/a><\/p>\n <\/div>\n<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n

\n
\n\t\t
\n\t\t \t\t\t

Reference:\n<\/h4>\n\t\t\t\t\t\t
    \n
  1. ROCTAVIAN\u2122 (valoctocogene roxaparvovec-rvox). Prescribing Information. BioMarin Pharmaceutical Inc.; 2023.\n<\/span><\/li>\n <\/ol>\n\t\t\t\t\t<\/div>\n\t<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"acf":[],"yoast_head":"\nGene therapy for severe hemophilia A | ROCTAVIAN\u2122 (valoctocogene roxaparvovec-rvox) for Healthcare Professionals<\/title>\n<meta name=\"description\" content=\"ROCTAVIAN\u2122 is the only gene therapy treatment option for adults with severe hemophilia A without active factor VIII inhibitors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gene therapy for severe hemophilia A | ROCTAVIAN\u2122 (valoctocogene roxaparvovec-rvox) for Healthcare Professionals\" \/>\n<meta property=\"og:description\" content=\"ROCTAVIAN\u2122 is the only gene therapy treatment option for adults with severe hemophilia A without active factor VIII inhibitors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/\" \/>\n<meta property=\"og:site_name\" content=\"BioMarin Roctavian HCP EN-US\" \/>\n<meta property=\"article:modified_time\" content=\"2023-12-21T09:51:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/wp-content\/uploads\/sites\/3\/2023\/08\/ROC-HCP.png?v=0.95\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"512\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Gene therapy for severe hemophilia A | ROCTAVIAN\u2122 (valoctocogene roxaparvovec-rvox) for Healthcare Professionals\" \/>\n<meta name=\"twitter:description\" content=\"ROCTAVIAN\u2122 is the only gene therapy treatment option for adults with severe hemophilia A without active factor VIII inhibitors.\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/wp-content\/uploads\/sites\/3\/2023\/08\/ROC-HCP-2.png?v=1.7\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/\",\"url\":\"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/\",\"name\":\"Gene therapy for severe hemophilia A | ROCTAVIAN\u2122 (valoctocogene roxaparvovec-rvox) for Healthcare Professionals\",\"isPartOf\":{\"@id\":\"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/#website\"},\"datePublished\":\"2023-05-22T11:33:29+00:00\",\"dateModified\":\"2023-12-21T09:51:54+00:00\",\"description\":\"ROCTAVIAN\u2122 is the only gene therapy treatment option for adults with severe hemophilia A without active factor VIII inhibitors.\",\"breadcrumb\":{\"@id\":\"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Home\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/#website\",\"url\":\"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/\",\"name\":\"BioMarin Roctavian HCP EN-US\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gene therapy for severe hemophilia A | ROCTAVIAN\u2122 (valoctocogene roxaparvovec-rvox) for Healthcare Professionals","description":"ROCTAVIAN\u2122 is the only gene therapy treatment option for adults with severe hemophilia A without active factor VIII inhibitors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/","og_locale":"en_US","og_type":"article","og_title":"Gene therapy for severe hemophilia A | ROCTAVIAN\u2122 (valoctocogene roxaparvovec-rvox) for Healthcare Professionals","og_description":"ROCTAVIAN\u2122 is the only gene therapy treatment option for adults with severe hemophilia A without active factor VIII inhibitors.","og_url":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/","og_site_name":"BioMarin Roctavian HCP EN-US","article_modified_time":"2023-12-21T09:51:54+00:00","og_image":[{"width":1024,"height":512,"url":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/wp-content\/uploads\/sites\/3\/2023\/08\/ROC-HCP.png?v=0.95","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_title":"Gene therapy for severe hemophilia A | ROCTAVIAN\u2122 (valoctocogene roxaparvovec-rvox) for Healthcare Professionals","twitter_description":"ROCTAVIAN\u2122 is the only gene therapy treatment option for adults with severe hemophilia A without active factor VIII inhibitors.","twitter_image":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/wp-content\/uploads\/sites\/3\/2023\/08\/ROC-HCP-2.png?v=1.7","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/","url":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/","name":"Gene therapy for severe hemophilia A | ROCTAVIAN\u2122 (valoctocogene roxaparvovec-rvox) for Healthcare Professionals","isPartOf":{"@id":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/#website"},"datePublished":"2023-05-22T11:33:29+00:00","dateModified":"2023-12-21T09:51:54+00:00","description":"ROCTAVIAN\u2122 is the only gene therapy treatment option for adults with severe hemophilia A without active factor VIII inhibitors.","breadcrumb":{"@id":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/hcp.biomarin.com\/en-us\/roctavian\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/"},{"@type":"ListItem","position":2,"name":"Home"}]},{"@type":"WebSite","@id":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/#website","url":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/","name":"BioMarin Roctavian HCP EN-US","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/wp-json\/wp\/v2\/pages\/5"}],"collection":[{"href":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/wp-json\/wp\/v2\/comments?post=5"}],"version-history":[{"count":98,"href":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/wp-json\/wp\/v2\/pages\/5\/revisions"}],"predecessor-version":[{"id":3007,"href":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/wp-json\/wp\/v2\/pages\/5\/revisions\/3007"}],"wp:attachment":[{"href":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/wp-json\/wp\/v2\/media?parent=5"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}